AgingResearch.NewsJoin free

ANTI-COV-2 therapeutics

Intervention

1 paper studies it1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: American Association of Immunologists and others
  • Animals1

Outcomes

1

Immunocytopathic features

downin M. auratus1

1 study

  1. ANTI-COV-2 therapeutics decrease immunocytopathic features in M. auratus.

    “These immunocytopathic features were induced in pre-clinical COVID models (ALO and hamster) and reversed with effective anti-CoV-2 therapeutics in hamsters.”

    Animalsin hamsters challenged with SARS-CoV-2

    COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis

    EBioMedicineJul 20, 2022

Latest

Related